Member Info for Ivyspivey

Summary of Merkeks comments during her visit to Georgia
Buys Russian Gas as it is cheaper but would be happy to buy Azeri gas.
Now imagine if a low cost supply from Georgia could compete with Russian Gas now that would please the US

http://cbw.ge/economy/the-gas-storage-facility-is-a-strategic-object-that-will-have-social-purpose/

http://cbw.ge/economy/angela-merkel-we-cant-refuse-to-cooperate-with-russia-in-oil-and-gas-direction/

http://cbw.ge/georgia/germany-will-build-energy-terminal-to-reduce-dependence-on-russia/

http://cbw.ge/economy/georgia-and-germany-to-sign-agreements-of-193-million-eur/

RR
Think your are right
AIM is a roller coaster and the best of times but expecting more big wheel than big dipper

Agree with you but think it is an LSE issue as saw it under the MTFB ticker on official RNS site and it was reported on Nasdaq

Good find Chris-A reminder

https://www.kyivpost.com/ukraine-politics/ministry-us-frontera-resources-longfellow-propose-hydrocarbons-production-agreement-ukraine.html

Jim I
Not on last 2 RNSs but on NDA acceptance one

Hi Jimzi
There plans will be well advanced and I am confident the 3k or so they say as the. cost of patient treatment is tested and also they will accurately know the costs and anticipated sales for the next few years.

Rebarm,
Cheers.I usually meet up with GL at Jeffries in November or earlier and when I do I will get a much better insight to their expectations.
As usual anything material will appear in an RNS but it gives me an opportunity to ask certain questions and from the answers I am able to get a pretty good understanding of how things are progressing so am confident of having a decent insight.
As I have said before the detail of any deal and the labelling of a Iclaprim will have a major influence on the commercial success of Iclaprim so sure we will be in a good position to predict the likely commercial outcome of Iclaprim with a high degree of reliability

Rebarm,
Thoughtful post and yes always manage a few w/end beers.
Dont want to repeat what I have already said but commercial success will be influenced by US commercial pathway and labelling neither of which we know final details yet.
I am sure that by end Nov so 2-3 months before Approval we will have a very good opportunity to assess the specific commercial expectations with Iclaprim and that will give a very good insight into how much MTFB are expecting.
This area is one I am much more comfortable in predicting rather than the science.
MTFB have a specific model to explain why using Iclaprim should be used rather than Vanco mycin and the cost I am sure will be acceptable to the purchasing authorities and will not compete directly with the generic Vancomycin prices.
There will be lots of give support and all these new institutions have bought in expecting a big rise in the SP and they would all have a great insight into the likely sales projections before buying in.
Hope this helps

Bridget/Vinny
Make you a promise.
If this comes good we will all be happy
If it goes belly up I will give you a cat each.Make your choice Chocolate Smoke Or Torteshell both Persians or a Farm Moggy.

Does that explain price action yesterday

Equally Botski
Not sure about a Nasdaq listing at this stage.I am very familiar with MTFB listing and yes lot of pain in short term but it is essential to their long term growth and not sure if that is case here.
You can raise money in US as JC knows scene well without a Nasdaq listing and really not sure if SCLP are ready for it and can be expensive.
Would think before any raise you would need to get the SP up and that needs news and you would probably have to think about a Grand Challenge timeline.
Is some speculation about sounding out a Nasdaq listing has led to the current SP malaise but I tend to think it is low volume/lack of news and “ delays” to trials that is causing current situation

SP closed at high UT so they can drop it to indicate a false drop.
When an institution has just paid 33.5p for 3m shares why would you sell at less.
Has to be seen as good news today but do someone wants it to appear as opposite.Fine by me as happy to hold into my 4th year and confident that will be great
Ask why have 3 Institutions Bought nearly 20m shares in orderly off market transactions this year plus the May raise.
Do you think they expect a nice return.Of course they do imo

Although no RNS has appeared on here it has been released under the MTFB name relating to AMP sale.
LSE ahead of game again

https://www.investegate.co.uk/amphion-innovations--amp-/rns/sale-of-partner-company-shares/201808210700093612Y/

About trends in biotech based inn Boston hub

https://t.co/5AtQxqx4kn

http://cbw.ge/economy/kfw-to-allocate-a-loan-of-150-mln-euros-to-georgia-for-construction-of-gasholder/